,ProtocolNum,ProtocolPhase,TA,PlannedEnrollment,ActualEnrollment,ActualRandomizedDosed,ActualEarlyTerminated,PercEnrollmentCompleted,PlannedSites,ActiveSites,CRO,LSO_ActualDate,DBL_ActualDate,CloseOut,numValsLSO,numValsDBL,PrimaryStudy_to_Synopsis,Synopsis_to_Protocol,FSS_to_FSI,LSI_to_LSO,AE,CM,DS,DV,EG,EX,FA,LB,MH,PR,SS,VS,Lock_duration,CloseOut_new
0,TAK-071-1002,I,NS,46,18,0.0,12.0,39.13%,1.0,1.0,PPD,2017-08-08,2018-05-24,289,5,5,,69.0,14.0,50.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,289
1,C16014  Korea Continuation,III,Oncology,40,41,0.0,8.0,102.50%,11.0,0.0,PPD,2019-12-02,2020-01-22,51,5,5,,,,971.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,51
2,C34007,I,Oncology,22,17,11.0,0.0,77.27%,5.0,0.0,IQVIA,2020-08-17,2020-11-25,59,5,5,,180.0,,327.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,100
3,TAK-438_115,I,GI,30,30,0.0,0.0,100.00%,1.0,0.0,IQVIA,2017-05-11,2017-05-17,6,5,5,,1061.0,16.0,42.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,6
4,TAK-438_302,III,GI,830,236,1.0,0.0,28.43%,68.0,0.0,IQVIA,2020-03-17,2020-07-07,112,5,5,,517.0,59.0,55.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,112
5,TAK-438_304,III,GI,530,530,1.0,0.0,100.00%,68.0,0.0,IQVIA,2019-04-12,2019-09-05,146,5,5,,-15.0,29.0,73.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,146
6,TAK-935-1005,I,NS,9,9,0.0,0.0,100.00%,1.0,1.0,PPD,2016-11-09,2017-01-11,63,5,5,,60.0,28.0,36.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,63
7,TAK-418-1001,I,NS,40,40,40.0,2.0,100.00%,1.0,1.0,PRA,2018-05-12,2018-06-07,26,5,5,,247.0,42.0,179.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,26
8,TAK-418-0004,I,NS,16,7,6.0,1.0,43.75%,1.0,0.0,PRA,2020-03-19,2020-11-03,132,5,5,,168.0,-57.0,16.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,19.0,229
9,Lubiprostone-3001,III,NonCore,204,173,0.0,0.0,84.80%,20.0,0.0,IQVIA,2017-01-23,2017-03-21,57,5,5,,,14.0,48.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,57
10,Lubiprostone-3002,III,NonCore,150,108,21.0,0.0,72.00%,13.0,0.0,IQVIA,2017-02-17,2017-04-21,63,5,5,,,22.0,42.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,63
11,Lubiprostone-3003,III,NonCore,204,172,0.0,0.0,84.31%,12.0,0.0,IQVIA,2017-06-05,2017-07-28,53,5,5,,,14.0,38.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,53
12,TAK-041-1002,I,NS,12,12,0.0,2.0,100.00%,1.0,1.0,IQVIA,2017-08-24,2017-10-19,56,5,5,,49.0,23.0,87.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,56
13,TAK-390MR_106,I,GI,40,40,0.0,0.0,100.00%,1.0,0.0,Hangzhou Tigermed Consulting,2018-02-08,2018-03-23,43,5,5,,1211.0,15.0,14.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,43
14,TAK-390MR_301,III,GI,450,37,0.0,34.0,8.22%,25.0,0.0,Hangzhou Tigermed Consulting,2017-10-30,2017-11-30,31,5,5,,1211.0,21.0,68.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,31
15,TAK-390MR_302,III,GI,200,217,0.0,12.0,108.50%,20.0,0.0,Hangzhou Tigermed Consulting,2018-04-10,2018-05-11,31,5,5,,1211.0,22.0,57.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,31
16,Alogliptin-1002,I,NonCore,72,72,0.0,4.0,100.00%,1.0,0.0,Atlant,2018-07-13,2018-09-12,61,5,5,,177.0,8.0,35.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,61
17,VedolizumabSC-1017,I,GI,24,24,0.0,0.0,100.00%,1.0,0.0,Celerion,2018-08-12,2018-09-19,38,5,5,,,20.0,167.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,38
18,Esomeprazole-1001,I,GI,52,52,0.0,2.0,100.00%,1.0,0.0,PRA,2017-05-13,2017-06-26,44,5,5,,130.0,26.0,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,44
19,Vedolizumab-2004,II,GI,17,17,16.0,0.0,100.00%,15.0,0.0,IQVIA,2018-05-09,2018-10-10,154,5,5,,101.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,154
20,C16029,III,Oncology,120,122,122.0,0.0,101.67%,117.0,30.0,PPD,2020-03-26,2020-09-04,162,5,5,,,,171.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,162
21,TBD-1-1MYTTL,I,GI,48,0,0.0,0.0,0,1.0,0.0,TBD,2020-04-16,2020-06-16,61,5,5,,126.0,19.0,71.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,61
22,TAK-935-2001,II,NS,18,18,0.0,4.0,100.00%,10.0,0.0,PRA,2018-10-12,2018-11-02,21,5,5,,170.0,65.0,120.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,21
23,TBD-1-1P9TDT,0,NS,100,0,0.0,0.0,0,3.0,0.0,TBD,2019-12-25,2020-02-19,56,5,5,,63.0,0.0,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,56
24,TAK-041-2001,II,NS,23,24,86.0,4.0,104.35%,1.0,1.0,PRA,2019-11-08,2020-02-07,34,5,5,,44.0,6.0,98.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,15.0,91
25,Vedolizumab-1019,I,GI,190,190,0.0,0.0,100.00%,1.0,0.0,Celerion,2020-07-06,2020-11-04,95,5,5,,170.0,3.0,139.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,121
26,TAK-954-1005,I,GI,6,6,6.0,1.0,100.00%,1.0,0.0,PRA,2018-06-01,2018-11-08,160,5,5,,92.0,21.0,14.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,160
27,TAK-954-1004,I,GI,11,10,0.0,0.0,90.91%,1.0,0.0,PRA,2017-07-24,2017-08-28,35,5,5,,144.0,0.0,27.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,35
28,TAK-954-1007,I,GI,32,32,0.0,1.0,100.00%,4.0,4.0,PRA,2019-08-12,2020-07-09,25,5,5,,28.0,11.0,13.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,332
29,TAK-954-1006,I,GI,24,25,0.0,2.0,104.17%,2.0,2.0,PRA,2018-09-10,2018-10-15,35,5,5,,39.0,33.0,13.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,35
30,TAK-954-2002,II,GI,200,1,0.0,1.0,0.50%,40.0,0.0,PRA,2018-08-29,2019-02-01,156,5,5,,60.0,0.0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,156
31,TAK-831-2001,II,NS,40,31,31.0,6.0,77.50%,3.0,2.0,PRA,2020-12-21,2021-02-15,56,5,5,,43.0,75.0,40.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,56
32,Cx611-0204,II,GI,80,84,0.0,0.0,105.00%,27.0,0.0,TFS,2020-07-31,2020-10-15,76,5,5,,0.0,0.0,227.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,76
33,TAK-906-1002,II,GI,48,51,0.0,3.0,106.25%,9.0,0.0,PRA,2018-03-11,2018-07-19,130,5,5,,162.0,9.0,19.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,130
34,TAK-925-1002,II,NS,20,20,20.0,2.0,100.00%,1.0,0.0,PRA,2018-11-07,2018-12-11,34,5,5,,36.0,26.0,50.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,34
35,Brigatinib-2002,II,Oncology,103,104,0.0,103.0,100.97%,89.0,61.0,TBD,2020-09-30,2021-03-23,57,5,5,,,,275.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,15.0,174
36,TAK-418-1003,I,NS,48,24,0.0,0.0,50.00%,2.0,0.0,PRA,2019-01-18,2019-02-12,25,5,5,,46.0,43.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,25
37,VedolizumabSC-1021,I,GI,24,24,0.0,0.0,100.00%,2.0,0.0,Celerion,2018-08-24,2018-10-05,42,5,5,,,16.0,167.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,42
38,VedolizumabSC-1022,I,GI,204,204,0.0,3.0,100.00%,2.0,0.0,Celerion,2018-11-21,2018-12-11,20,5,5,,,12.0,164.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20
39,TAK-788-1001,I,Oncology,68,68,0.0,0.0,100.00%,1.0,0.0,PRA,2019-01-18,2019-05-22,124,5,5,,65.0,21.0,37.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,124
40,TAK-935-2006,II,NS,124,141,0.0,15.0,113.71%,45.0,0.0,PPD,2020-06-09,2020-07-20,41,5,5,,,42.0,138.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,41
41,TAK-951-1001,I,GI,128,124,0.0,0.0,96.88%,1.0,0.0,PRA,2020-11-02,2021-03-02,116,5,5,,91.0,27.0,40.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,120
42,TAK-418-0002,0,NS,12,0,0.0,0.0,0.00%,1.0,0.0,0,2018-11-06,2018-11-07,1,5,5,,3.0,18.0,25.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1
43,TAK-935-2004,II,NS,30,20,0.0,2.0,66.67%,3.0,0.0,PPD,2020-07-13,2021-06-09,18,5,5,,74.0,28.0,24.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,331
44,TAK-925-2002,II,NS,40,28,28.0,0.0,70.00%,10.0,0.0,IQVIA,2020-11-25,2021-01-21,57,5,5,,54.0,44.0,8.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,57
45,TAK-925-2001,II,NS,42,25,25.0,2.0,59.52%,18.0,0.0,IQVIA,2020-04-02,2020-11-12,77,5,5,,22.0,12.0,11.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,224
46,TAK-906-1009,I,GI,12,12,0.0,0.0,100.00%,1.0,0.0,Celerion,2019-11-12,2020-01-06,55,5,5,,72.0,13.0,18.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,55
47,TAK-935-1008,I,NS,16,16,0.0,0.0,100.00%,1.0,0.0,Celerion,2020-08-16,2020-09-18,33,5,5,,105.0,2.0,30.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,33
48,TAK-994-1006,I,NS,54,54,0.0,0.0,100.00%,2.0,0.0,Celerion,2021-04-05,2021-05-07,32,5,5,,63.0,14.0,24.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,32
49,TAK-951-1004,I,GI,40,32,0.0,0.0,80.00%,1.0,0.0,Celerion,2021-05-16,2021-06-14,29,5,5,,87.0,94.0,28.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,29
50,TAK-925-1013,I,NS,16,16,0.0,0.0,100.00%,1.0,0.0,Celerion,2020-03-13,2020-09-09,42,5,5,,60.0,14.0,16.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,180
51,TAK-935-1004,I,NS,32,0,0.0,0.0,0.00%,1.0,0.0,PRA,2020-11-14,2021-03-18,124,5,5,,67.0,11.0,24.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,124
52,TAK-994-1503,I,NS,18,19,19.0,5.0,105.56%,1.0,1.0,PRA,2020-12-30,2021-03-11,29,5,5,,70.0,21.0,27.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.0,71
53,C13008,III,GI,"2,200","2,244",0.0,1502.0,102.00%,462.0,1.0,IQVIA,2017-10-31,2018-01-29,90,5,5,,,,1854.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,90
54,C16003,I,Oncology,63,0,0.0,0.0,0.00%,7.0,0.0,IQVIA,2012-10-22,2013-03-25,154,5,5,,,,126.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,154
55,C16005,II,Oncology,61,65,0.0,64.0,106.56%,16.0,0.0,PPD,2013-10-20,2014-04-07,169,5,5,,,,600.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,169
56,C16006,II,Oncology,61,61,0.0,27.0,100.00%,31.0,0.0,PPD,2016-12-29,2017-05-03,125,5,5,,,,955.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,125
57,C16007,I,Oncology,32,27,0.0,0.0,84.38%,10.0,0.0,ICON,2013-12-06,2014-02-12,68,5,5,,,,365.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,68
58,C16008,II,Oncology,60,64,0.0,54.0,106.67%,19.0,0.0,PPD,2013-10-14,2014-02-28,137,5,5,,,,364.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,137
59,C15002,I,Oncology,99,56,0.0,0.0,56.57%,14.0,1.0,PPD,2013-07-15,2013-09-30,77,5,5,,,,104.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,77
60,C15001,I,Oncology,89,62,0.0,1.0,69.66%,6.0,1.0,PPD,2012-02-15,2012-03-16,30,5,5,,,,91.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,30
61,C15003,I,Oncology,72,72,0.0,3.0,100.00%,10.0,0.0,PPD,2013-08-25,2013-10-28,64,5,5,,,,185.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,64
62,C15005,I,Oncology,66,37,0.0,3.0,56.06%,3.0,1.0,PPD,2012-05-22,2012-08-17,87,5,5,,,,112.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,87
63,C25002,II,Oncology,42,36,0.0,0.0,85.71%,24.0,5.0,ICON,2016-10-12,2016-12-03,52,5,5,,,,183.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,52
64,C25003,III,Oncology,23,"1,309",0.0,0.0,5691.30%,258.0,223.0,ICON,2017-04-20,2017-06-12,53,5,5,,,,463.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,53
65,C16010,III,Oncology,41,838,838.0,0.0,2043.90%,150.0,114.0,PPD,2014-10-30,2015-01-15,77,5,5,,,15.0,156.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,77
66,C14012,III,Oncology,354,155,274.0,0.0,43.79%,180.0,1.0,IQVIA,2015-06-30,2015-09-15,77,5,5,,,,237.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,77
67,C27001,I,Oncology,218,176,0.0,5.0,80.73%,2.0,0.0,Hammersmith Medicines Research,2012-12-18,2013-01-17,30,5,5,,,,81.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,30
68,TAK-390MR_206,II,NonCore,104,0,0.0,0.0,0.00%,56.0,0.0,IQVIA,2014-01-21,2014-03-13,51,5,5,,248.0,,42.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,51
69,TBD-18831,I,Oncology,50,0,0.0,0.0,0,1.0,0.0,TBD,2015-05-17,2015-06-15,29,5,5,,,,54.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,29
70,TAK-931-1002,I,Oncology,80,80,0.0,80.0,100.00%,2.0,0.0,PPD,2019-12-20,2020-04-06,108,5,5,,27.0,,136.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,108
71,TAK-931-1003,I,Oncology,44,21,21.0,21.0,47.73%,4.0,0.0,PRA,2019-12-03,2020-04-07,126,5,5,,51.0,,120.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,126
72,TAK-931-2001,II,Oncology,142,101,0.0,101.0,71.13%,15.0,0.0,PRA,2020-08-24,2020-11-06,74,5,5,,120.0,,320.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,74
73,C16047,II,Oncology,60,61,0.0,43.0,101.67%,25.0,35.0,PRA,2020-01-31,2020-03-17,46,5,5,,76.0,,184.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,46
74,C31008,I,Oncology,46,28,0.0,0.0,60.87%,4.0,0.0,IQVIA,2019-08-28,2019-10-24,57,5,5,,118.0,,131.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,57
75,C34004,II,Oncology,122,49,0.0,45.0,40.16%,50.0,0.0,PRA,2019-01-31,2019-04-11,70,5,5,,348.0,,182.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,70
76,C34003,II,Oncology,48,41,0.0,41.0,85.42%,25.0,1.0,PRA,2018-10-15,2019-05-07,204,5,5,,114.0,,82.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,204
77,C34005,II,Oncology,55,43,0.0,0.0,78.18%,15.0,0.0,PRA,2020-07-27,2020-09-04,39,5,5,,68.0,,615.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,39
78,C25010,II,Oncology,30,39,39.0,39.0,130.00%,9.0,0.0,IQVIA,2018-08-02,2018-09-12,41,5,5,,,16.0,373.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,41
79,Pevonedistat-1014,I,Oncology,45,44,0.0,3.0,97.78%,8.0,6.0,PRA,2019-01-07,2019-11-13,119,5,5,,,,21.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,71.0,310
80,Pevonedistat-1013,I,Oncology,8,8,0.0,1.0,100.00%,2.0,0.0,PRA,2018-02-09,2018-04-09,59,5,5,,,,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,59
81,Leuprorelin-4001,IV,NonCore,300,307,0.0,23.0,102.33%,12.0,0.0,Hangzhou Tigermed Consulting,2018-11-19,2019-01-17,59,5,5,,-64.0,14.0,689.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,59
82,TAK-390MR-1001,I,NonCore,104,116,0.0,16.0,111.54%,1.0,0.0,PRA,2017-07-14,2017-08-16,33,5,5,,229.0,26.0,20.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,33
83,TAK-041-1001,I,NS,114,114,0.0,3.0,100.00%,1.0,1.0,PPD,2019-09-22,2019-11-14,53,5,5,,-213.0,49.0,75.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,53
84,C31006,II,Oncology,141,141,0.0,141.0,100.00%,55.0,0.0,GEICAM,2019-11-29,2020-04-06,129,5,5,,203.0,,564.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,129
85,Vortioxetine-4001,IV,NS,352,361,0.0,67.0,102.56%,16.0,0.0,IQVIA,2017-06-09,2017-07-31,52,5,5,,148.0,15.0,46.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,52
86,Vedolizumab-1015,II,GI,24,24,0.0,6.0,100.00%,4.0,0.0,PRA,2018-07-10,2018-08-29,50,5,5,,64.0,,383.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,50
87,Vedolizumab-1014,I,GI,16,16,0.0,0.0,100.00%,1.0,0.0,PRA,2018-07-26,2018-11-14,111,5,5,,112.0,15.0,126.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,111
88,Vedolizumab-3034,III,GI,204,215,215.0,108.0,105.39%,30.0,0.0,IQVIA,2019-02-28,2019-06-13,105,5,5,,111.0,21.0,70.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,105
89,TAK-071-1001,I,NS,186,177,0.0,1.0,95.16%,1.0,1.0,PPD,2017-06-08,2017-08-14,67,5,5,,128.0,13.0,15.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,67
90,TAK-906-1003,I,GI,12,12,0.0,1.0,100.00%,1.0,0.0,PRA,2017-07-11,2017-08-18,38,5,5,,27.0,18.0,18.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,38
91,Pevonedistat-1015,I,Oncology,20,20,0.0,20.0,100.00%,4.0,0.0,PRA,2019-05-10,2020-09-11,67,5,5,,,,11.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,11.0,490
92,TAK-906-1007,I,GI,6,6,0.0,0.0,100.00%,1.0,0.0,Celerion,2020-09-29,2020-10-30,31,5,5,,25.0,43.0,28.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,31
93,TAK-906-1006,I,GI,12,12,0.0,0.0,100.00%,1.0,0.0,Celerion,2019-03-30,2019-05-04,35,5,5,,56.0,14.0,10.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,35
94,TAK-954-2003,II,GI,48,36,37.0,2.0,75.00%,1.0,0.0,PRA,2019-07-12,2020-10-16,46,5,5,,96.0,4.0,38.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,43.0,462
95,AP26113-11-101,II,Oncology,137,137,0.0,45.0,100.00%,10.0,0.0,TBD,2020-02-11,2020-07-30,169,5,5,,,,2044.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,23.0,170
96,AP26113-13-201,II,Oncology,222,222,0.0,167.0,100.00%,80.0,0.0,PRA,2016-11-14,2016-12-23,39,5,5,,0.0,,420.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,39
97,AP32788-15-101,II,Oncology,336,226,186.0,183.0,67.26%,95.0,28.0,PRA,2020-05-29,2020-09-04,98,5,5,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,98
98,AP26113-15-107,I,Oncology,1,0,0.0,0.0,0.00%,1.0,0.0,INC Research,2016-12-04,2017-06-26,204,5,5,,,,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,204
99,AP26113-15-108,I,Oncology,1,0,0.0,0.0,0.00%,1.0,0.0,INC Research,2016-11-03,2017-06-26,235,5,5,,,,7.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,235
100,AP26113-13-301,III,Oncology,270,275,45.0,126.0,101.85%,150.0,18.0,PRA Health Sciences,2018-02-19,2019-09-20,122,5,5,,,,188.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,15.0,578
101,Brigatinib-2001,II,Oncology,80,72,0.0,45.0,90.00%,1.0,0.0,TBD,2019-09-03,2019-11-12,70,5,5,,132.0,,144.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,70
102,TAK-831-1005,I,NS,48,50,50.0,3.0,104.17%,1.0,0.0,PRA,2018-09-09,2018-10-02,23,5,5,,8.0,0.0,58.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,23
103,Actovegin-3001,III,NonCore,366,366,0.0,3.0,100.00%,20.0,0.0,Atlant,2019-08-20,2019-11-22,94,5,5,,337.0,95.0,168.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,94
104,VedolizumabSC-1018,I,GI,102,102,0.0,1.0,100.00%,1.0,0.0,Celerion,2018-09-21,2018-10-05,14,5,5,,,26.0,164.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14
105,Brigatinib-1001,I,Oncology,20,24,0.0,24.0,120.00%,14.0,14.0,PRA,2020-03-25,2020-10-12,201,5,5,,55.0,,29.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,201
106,TIMP-GLIA-5001,0,GI,20,16,16.0,2.0,80.00%,2.0,0.0,PRA,2019-04-29,2020-05-26,144,5,5,,71.0,62.0,40.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,393
107,Ponatinib-3001,III,Oncology,230,174,174.0,80.0,75.65%,120.0,116.0,PRA,2021-02-17,2021-05-19,91,5,5,,191.0,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,91
108,AP24534-10-201,II,Oncology,449,244,0.0,0.0,54.34%,42.0,0.0,INC Research,2015-10-10,2017-03-31,538,5,5,,,,1440.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,538
109,AP24534-14-203,II,Oncology,276,283,291.0,140.0,102.54%,150.0,60.0,PRA,2019-07-20,2020-01-17,52,5,5,,,,66.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,44.0,181
110,TAK-653-1003,I,NS,24,24,0.0,0.0,100.00%,1.0,0.0,PRA,2019-06-14,2019-07-15,31,5,5,,38.0,21.0,15.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,31
111,TBD-1-30EP0F,0,NS,40,0,0.0,0.0,0,1.0,0.0,TBD,2019-02-07,2019-02-26,19,5,5,,59.0,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,19
112,TAK-994-1001,I,NS,160,121,0.0,3.0,75.63%,2.0,0.0,PRA,2020-03-29,2020-09-28,87,5,5,,42.0,21.0,25.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,71.0,183
113,TAK-954-1009,I,GI,6,6,0.0,0.0,100.00%,1.0,0.0,Celerion,2019-05-12,2019-06-14,33,5,5,,50.0,18.0,49.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,33
114,TAK-925-1009,I,NS,16,16,0.0,0.0,100.00%,1.0,0.0,Celerion,2019-12-03,2020-05-12,52,5,5,,52.0,0.0,21.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,161
115,MT203-2004,II,NonCore,36,7,0.0,0.0,19.44%,15.0,0.0,IQVIA,2016-11-01,2016-12-19,48,5,5,,60.0,21.0,292.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,48
116,AP24534-15-303,III,Oncology,44,44,0.0,3.0,100.00%,90.0,0.0,INC Research,2020-11-26,2021-03-22,116,5,5,,,14.0,1129.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,116
117,TAK-788-1005,I,Oncology,14,14,0.0,0.0,100.00%,1.0,0.0,Celerion,2020-07-21,2020-09-14,55,5,5,,274.0,,20.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,55
118,TAK-788-1002,I,Oncology,6,7,0.0,0.0,116.67%,1.0,0.0,Celerion,2019-03-11,2019-08-15,157,5,5,,159.0,,38.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,157
119,TAK-788-1004,I,Oncology,26,26,0.0,23.0,100.00%,8.0,0.0,PRA,2020-12-17,2021-03-15,88,5,5,,94.0,,31.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,88
120,TAK-788-1006,I,Oncology,28,24,0.0,0.0,85.71%,1.0,0.0,Celerion,2019-08-16,2019-09-25,40,5,5,,54.0,,42.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,40
121,TBD-1-304JYV,0,GI,14,14,0.0,0.0,100.00%,1.0,0.0,Parexel,2018-12-06,2019-01-31,56,5,5,,35.0,21.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,56
122,TAK-935-2008,II,NS,24,24,24.0,9.0,100.00%,6.0,0.0,PRA,2020-10-21,2021-02-16,118,5,5,,72.0,8.0,219.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,118
123,TAK-831-1008,I,NS,6,6,0.0,0.0,100.00%,1.0,0.0,Celerion,2020-04-01,2020-09-14,166,5,5,,61.0,1.0,34.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,166
124,C16011,III,Oncology,248,177,177.0,0.0,71.37%,74.0,30.0,PPD,2019-02-20,2019-04-23,62,5,5,,,,-100.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,62
125,LuAA21004_402,IV,NS,"1,100",995,0.0,0.0,90.45%,65.0,0.0,IQVIA,2019-04-25,2019-06-25,61,5,5,,61.0,8.0,360.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,61
126,Vonoprazan-2001,II,GI,214,120,0.0,0.0,56.07%,38.0,0.0,IQVIA,2018-10-05,2019-02-20,138,5,5,,350.0,84.0,28.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,138
127,C16013,I,Oncology,24,43,0.0,2.0,179.17%,8.0,8.0,PPD,2014-07-14,2014-10-02,80,5,5,,,,27.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,80
128,INK128-001,I,Oncology,170,198,0.0,0.0,116.47%,16.0,17.0,Synteract,2015-10-02,2016-03-04,154,5,5,,,,245.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,154
129,INK128-002,I,Oncology,60,39,0.0,4.0,65.00%,12.0,1.0,Synteract,2013-05-29,2013-06-25,27,5,5,,,,216.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,27
130,INK128-003,I,Oncology,95,69,0.0,11.0,72.63%,3.0,4.0,Sarah Cannon Research Institut,2014-05-29,2014-07-30,62,5,5,,,,310.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,62
131,C16014,III,Oncology,60,748,748.0,0.0,1246.67%,200.0,127.0,PPD,2018-02-15,2018-03-27,40,5,5,,,,777.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,40
132,C16015,I,Oncology,40,40,0.0,39.0,100.00%,10.0,0.0,ICON,2015-03-03,2015-04-09,37,5,5,,,,14.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,37
133,C16017,II,Oncology,44,29,0.0,26.0,65.91%,26.0,0.0,PPD,2017-03-23,2017-05-10,48,5,5,,,,490.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,48
134,C15009,I,Oncology,64,64,0.0,63.0,100.00%,4.0,8.0,PPD,2016-06-30,2016-09-13,75,5,5,,,,213.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,75
135,C16016,I,Oncology,6,7,0.0,2.0,116.67%,1.0,1.0,ICON,2015-02-20,2015-02-28,8,5,5,,,,100.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,8
136,C25001,III,Oncology,136,132,0.0,0.0,97.06%,52.0,10.0,ICON,2016-05-30,2016-07-20,51,5,5,,,,304.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,51
137,C28001,I,Oncology,150,122,89.0,0.0,81.33%,17.0,0.0,IQVIA,2017-04-11,2017-06-22,72,5,5,,,,193.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,72
138,MA25101,IV,Oncology,0,22,4.0,0.0,0,0.0,0.0,IQVIA,2018-09-21,2018-11-15,55,5,5,,,,255.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,55
139,C25006,IV,Oncology,49,50,50.0,0.0,102.04%,40.0,0.0,IQVIA,2021-05-04,2021-06-25,52,5,5,,,,572.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,52
140,C16001,I,Oncology,116,116,0.0,35.0,100.00%,7.0,0.0,Dobbs Consulting,2012-04-20,2012-05-24,34,5,5,,,,101.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,34
141,C16002,I,Oncology,34,31,0.0,6.0,91.18%,6.0,4.0,Dobbs Consulting,2014-10-20,2014-12-20,61,5,5,,,,749.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,61
142,C15010,I,Oncology,64,48,0.0,0.0,75.00%,6.0,0.0,IQVIA,2016-02-15,2016-09-12,210,5,5,,,,287.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,210
143,C32001,I,Oncology,101,85,2.0,0.0,84.16%,10.0,0.0,IQVIA,2017-03-24,2017-04-19,26,5,5,,,,179.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,26
144,C16018,I,Oncology,45,48,0.0,48.0,106.67%,4.0,0.0,PPD,2015-03-25,2015-05-19,55,5,5,,,,62.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,55
145,C25007,IV,Oncology,60,61,8.0,0.0,101.67%,21.0,0.0,IQVIA,2016-03-24,2016-05-23,60,5,5,,,,379.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,60
146,C34001,I,Oncology,182,144,0.0,0.0,79.12%,16.0,0.0,IQVIA,2018-07-13,2019-02-26,228,5,5,,,,95.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,228
147,C16020,II,Oncology,148,148,0.0,0.0,100.00%,26.0,0.0,PPD,2016-06-29,2016-08-24,56,5,5,,,,406.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,56
148,C31001,II,Oncology,118,86,3.0,0.0,72.88%,40.0,0.0,IQVIA,2018-07-03,2018-09-07,66,5,5,,74.0,,179.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,66
149,C27002,II,Oncology,125,48,138.0,0.0,38.40%,25.0,0.0,IQVIA,2016-03-31,2016-06-14,75,5,5,,,,406.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,75
150,C27003,II,Oncology,100,80,108.0,0.0,80.00%,28.0,0.0,IQVIA,2015-12-14,2016-03-28,105,5,5,,,,259.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,105
151,C15011,I,Oncology,52,51,0.0,11.0,98.08%,4.0,0.0,PPD,2017-06-05,2017-08-28,84,5,5,,,,322.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,84
152,C27005,I,Oncology,40,40,0.0,1.0,100.00%,1.0,2.0,In-House,2014-04-19,2014-05-27,38,5,5,,,,21.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,38
153,C25004,II,Oncology,67,59,0.0,59.0,88.06%,28.0,0.0,IQVIA,2020-12-18,2021-01-28,41,5,5,,,,450.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,41
154,C16021,III,Oncology,706,727,716.0,0.0,102.97%,229.0,166.0,PPD,2019-08-12,2019-09-18,37,5,5,,,,308.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,37
155,C26002,II,Oncology,38,14,7.0,0.0,36.84%,35.0,0.0,IQVIA,2015-10-23,2016-03-28,157,5,5,,,,143.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,157
156,C26003,II,Oncology,43,18,0.0,0.0,41.86%,35.0,0.0,IQVIA,2015-11-13,2016-04-27,166,5,5,,,,136.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,166
157,C16010CCS,III,Oncology,115,115,0.0,7.0,100.00%,11.0,0.0,PPD,2015-07-12,2015-08-19,38,5,5,,,,69.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,38
158,C26004,II,Oncology,95,12,0.0,12.0,12.63%,21.0,0.0,IQVIA,2015-10-08,2016-01-12,96,5,5,,,,119.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,96
159,C34002,II,Oncology,106,39,12.0,0.0,36.79%,15.0,0.0,IQVIA,2018-09-27,2019-04-23,208,5,5,,,,182.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,208
160,C31004,II,Oncology,242,245,245.0,245.0,101.24%,77.0,0.0,PRA,2019-04-30,2019-07-29,90,5,5,,412.0,,187.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,90
161,Pevonedistat-2001,II,Oncology,120,123,0.0,9.0,102.50%,72.0,26.0,PPD,2019-09-04,2020-02-12,55,5,5,,,,805.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,72.0,161
162,Pevonedistat-1012,I,Oncology,37,23,0.0,20.0,62.16%,9.0,4.0,PPD,2018-04-16,2020-01-08,63,5,5,,,,147.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,68.0,632
163,C31005,II,Oncology,96,95,37.0,87.0,98.96%,55.0,3.0,PRA,2020-03-06,2020-04-30,55,5,5,,199.0,,696.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,55
164,AD-4833/TOMM40_301,III,NS,"3,500","3,494",0.0,3398.0,99.83%,59.0,65.0,IQVIA,2018-08-07,2018-09-18,42,5,5,,295.0,27.0,960.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,42
165,AD-4833/TOMM40_302,III,NS,675,678,0.0,0.0,100.44%,4.0,0.0,Covance,2014-12-18,2015-03-18,90,5,5,,295.0,0.0,28.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,90
166,AD-4833-TOMM40_303,III,NS,149,40,4.0,0.0,26.85%,44.0,0.0,IQVIA,2018-05-09,2018-09-19,133,5,5,,425.0,0.0,175.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,133
167,e0035,I,NS,11,9,0.0,3.0,81.82%,1.0,0.0,In-House,2015-03-02,2015-03-04,2,5,5,,27.0,11.0,5.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2
168,Leuprorelin-5001,IV,NonCore,100,108,0.0,1.0,108.00%,8.0,0.0,Hangzhou Tigermed Consulting,2018-09-30,2019-01-30,122,5,5,,55.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,122
169,MLN0002-2003,II,GI,80,90,90.0,23.0,112.50%,71.0,5.0,PRA,2020-05-26,2020-05-27,1,5,5,,794.0,26.0,156.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,24.0,1
170,MLN0002-3026,III,GI,758,769,0.0,243.0,101.45%,331.0,0.0,IQVIA,2019-01-18,2019-03-08,49,5,5,,77.0,,478.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,49
171,MLN0002-3028,III,GI,100,80,2.0,0.0,80.00%,75.0,0.0,IQVIA,2018-02-21,2018-04-06,44,5,5,,140.0,,448.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,44
172,MLN0002SC-3030,III,GI,746,747,28.0,387.0,100.13%,348.0,0.0,IQVIA,2018-05-31,2018-11-07,160,5,5,,77.0,0.0,-348.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,160
173,MLN0002SC-3031,III,GI,645,644,0.0,169.0,99.84%,222.0,0.0,IQVIA,2019-05-06,2019-09-13,57,5,5,,77.0,21.0,376.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,130
174,MLN9708_101,I,Oncology,40,12,0.0,0.0,30.00%,34.0,0.0,PPD,2018-01-15,2018-03-09,53,5,5,,,,210.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,53
175,MLN0002SC-3027,III,GI,400,203,1.0,0.0,50.75%,250.0,0.0,IQVIA,2018-05-30,2018-07-03,34,5,5,,77.0,-42.0,364.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,34
176,TAK-831-1001,I,NS,120,280,29.0,0.0,233.33%,1.0,0.0,IQVIA,2016-06-09,2016-10-12,125,5,5,,127.0,14.0,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,125
177,TAK-831-1003,I,NS,22,16,0.0,0.0,72.73%,1.0,0.0,IQVIA,2016-08-30,2016-11-16,78,5,5,,148.0,16.0,26.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,78
178,TAK-831-1501,II,NS,65,63,0.0,0.0,96.92%,6.0,0.0,IQVIA,2018-12-27,2019-02-11,46,5,5,,54.0,27.0,91.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,46
179,TAK-831-2002,II,NS,234,307,257.0,31.0,131.20%,48.0,0.0,IQVIA,2021-01-12,2021-04-07,36,5,5,,47.0,46.0,95.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,13.0,85
180,TAK-831-1006,I,NS,16,16,0.0,0.0,100.00%,1.0,0.0,Celerion,2018-12-22,2019-01-30,39,5,5,,61.0,16.0,49.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,39
181,TAK-831-1004,I,NS,16,15,0.0,1.0,93.75%,1.0,0.0,PRA,2017-05-24,2017-07-24,61,5,5,,40.0,27.0,22.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,61
182,SYR-322_104,I,NonCore,48,47,0.0,1.0,97.92%,4.0,0.0,Covance,2013-11-22,2014-03-10,108,5,5,,,,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,108
183,SYR-322MET_303,III,NonCore,659,651,0.0,134.0,98.79%,71.0,22.0,Covance,2015-10-05,2016-06-29,268,5,5,,142.0,41.0,188.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,268
184,SYR322MET-1003,I,NonCore,24,24,0.0,0.0,100.00%,1.0,1.0,PPD,2016-04-27,2016-06-15,49,5,5,,125.0,22.0,12.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,49
185,TAK-063_102,I,RGH,27,27,0.0,7.0,100.00%,1.0,0.0,Covance,2014-08-28,2015-08-13,350,5,5,,276.0,39.0,38.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,350
186,TAK-063_103,I,RGH,18,13,0.0,1.0,72.22%,1.0,0.0,Covance,2014-03-12,2014-06-12,92,5,5,,209.0,57.0,13.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,92
187,TAK-491_305,III,NonCore,600,582,12.0,0.0,97.00%,30.0,0.0,IQVIA,2017-10-27,2017-12-08,42,5,5,,71.0,25.0,57.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,42
188,TAK-491_112,I,NonCore,64,53,0.0,0.0,82.81%,1.0,0.0,IQVIA,2017-03-19,2017-05-03,45,5,5,,39.0,3.0,25.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,45
189,TAK-653-1001,I,NS,72,88,0.0,1.0,122.22%,1.0,0.0,PPD,2017-09-23,2017-10-20,27,5,5,,54.0,19.0,37.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,27
190,TAK-063-2002,II,RGH,160,115,0.0,0.0,71.88%,16.0,0.0,IQVIA,2016-07-27,2016-09-09,44,5,5,,72.0,6.0,57.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,44
191,TAK-390MR_207,II,NonCore,63,0,0.0,0.0,0.00%,58.0,2.0,IQVIA,2014-11-10,2014-12-18,38,5,5,,248.0,1.0,251.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,38
192,TAK-438_114,I,GI,36,33,0.0,0.0,91.67%,1.0,0.0,IQVIA,2017-08-18,2017-10-04,47,5,5,,0.0,,17.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,47
193,TAK-438_303,III,GI,480,288,4.0,0.0,60.00%,63.0,0.0,IQVIA,2017-07-27,2017-09-01,36,5,5,,91.0,21.0,44.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,36
194,TAK-438_305,III,GI,693,630,5.0,0.0,90.91%,72.0,0.0,IQVIA,2018-12-31,2019-11-18,322,5,5,,7.0,7.0,181.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,322
195,TAK-063_104,I,RGH,90,77,0.0,4.0,85.56%,1.0,0.0,Covance,2014-06-23,2014-08-20,58,5,5,,48.0,28.0,13.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,58
196,TAK-390MR_104,I,NonCore,240,247,0.0,38.0,102.92%,11.0,0.0,IQVIA,2014-01-19,2014-12-10,325,5,5,,440.0,81.0,366.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,325
197,TAK-935_101,I,NS,48,48,0.0,0.0,100.00%,1.0,0.0,PPD,2015-07-16,2015-09-10,56,5,5,,38.0,22.0,6.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,56
198,TAK-935_1002,I,NS,40,40,0.0,16.0,100.00%,1.0,0.0,PPD,2016-04-19,2016-06-17,59,5,5,,99.0,25.0,30.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,59
199,TAK-935_1003,I,NS,11,11,0.0,0.0,100.00%,1.0,0.0,PPD,2016-01-06,2016-03-04,58,5,5,,,14.0,47.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,58
200,TMX-67_204,II,NonCore,300,0,0.0,0.0,0.00%,85.0,0.0,Covance,2013-09-03,2013-12-09,97,5,5,,103.0,,740.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,97
201,TMX-67_206,II,NonCore,120,0,0.0,0.0,0.00%,40.0,0.0,Covance,2014-08-04,2014-10-14,71,5,5,,112.0,21.0,53.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,71
202,TMX-67_301,III,NonCore,"7,500","6,193",0.0,2737.0,82.57%,450.0,0.0,PPD,2017-05-15,2017-08-08,85,5,5,,137.0,7.0,294.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,85
203,Vedolizumab-4001,IV,GI,12,11,0.0,1.0,91.67%,8.0,0.0,PPD,2019-02-22,2019-04-05,42,5,5,,225.0,13.0,57.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,42
204,TAK-020-1001,I,NonCore,128,114,120.0,0.0,89.06%,1.0,0.0,IQVIA,2017-05-04,2017-07-25,82,5,5,,45.0,28.0,17.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,82
205,TAK-020-1002,I,NonCore,25,23,25.0,0.0,92.00%,1.0,0.0,IQVIA,2016-08-19,2016-11-07,80,5,5,,205.0,27.0,24.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,80
206,0624-209,III,NonCore,8,8,8.0,0.0,100.00%,10.0,0.0,Parexel,2017-06-23,2017-07-27,34,5,5,,69.0,1.0,108.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,34
207,71301,III,RGH,22,23,0.0,0.0,104.55%,32.0,0.0,IQVIA,2020-08-25,2020-10-22,58,5,5,,,58.0,435.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,58
208,91301,IV,NonCore,55,53,0.0,42.0,96.36%,40.0,0.0,Synteract,2020-02-28,2020-08-31,185,5,5,,,,801.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,185
209,241302,IV,RGH,40,53,0.0,0.0,132.50%,40.0,0.0,IQVIA,2019-06-07,2021-04-16,679,5,5,,496.0,0.0,231.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,679
210,471101,IV,NonCore,36,36,0.0,0.0,100.00%,20.0,0.0,IQVIA,2020-07-29,2020-11-09,103,5,5,,90.0,44.0,175.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,103
211,Cabozantinib-2001,II,Oncology,35,35,0.0,0.0,100.00%,19.0,0.0,MEDISCIENCE PLANNING INC,2018-10-23,2018-12-18,56,5,5,,,41.0,112.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,56
212,Cabozantinib-2003,II,Oncology,32,34,0.0,0.0,106.25%,18.0,0.0,Takeda PRA Development Center,2019-07-23,2019-09-19,58,5,5,,,15.0,175.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,58
213,Darvadstrocel-3002,III,GI,20,22,0.0,0.0,110.00%,7.0,0.0,MEDISCIENCE PLANNING INC,2020-07-20,2020-11-11,114,5,5,,206.0,22.0,167.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,114
214,C16028,II,Oncology,30,34,0.0,6.0,113.33%,20.0,0.0,EPS,2018-08-03,2018-10-02,60,5,5,,,18.0,364.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,60
215,TB-MC010034,I,Oncology,1,0,0.0,0.0,0.00%,5.0,0.0,Takeda PRA Development Center,2019-02-15,2019-05-15,89,5,5,,,14.0,1962.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,89
216,Niraparib-1001,I,Oncology,9,9,0.0,8.0,100.00%,1.0,0.0,Takeda PRA Development Center,2018-12-03,2019-05-20,168,5,5,,,4.0,41.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,168
217,SYR-472-3003,III,NonCore,107,107,0.0,25.0,100.00%,51.0,0.0,A2 Healthcare,2018-04-24,2018-06-18,55,5,5,,55.0,38.0,378.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,55
218,Vonoprazan-3001,III,GI,484,484,0.0,0.0,100.00%,45.0,0.0,EPS,2018-02-26,2018-05-29,92,5,5,,225.0,10.0,28.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,92
219,TAK-438ASA-1001,I,GI,552,548,0.0,0.0,99.28%,1.0,0.0,MEDISCIENCE PLANNING INC,2018-10-12,2018-12-27,76,5,5,,71.0,25.0,2.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,76
220,TAK-536/OCT-101,III,NonCore,30,27,0.0,4.0,90.00%,32.0,0.0,MEDISCIENCE PLANNING INC,2019-06-04,2019-07-23,49,5,5,,,38.0,371.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,49
221,TAK-831-1002,I,NS,40,40,0.0,0.0,100.00%,1.0,0.0,Takeda PRA Development Center,2019-06-19,2019-07-23,34,5,5,,78.0,10.0,28.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,34
222,TAK-906-1004,I,GI,24,24,0.0,0.0,100.00%,1.0,0.0,MEDISCIENCE PLANNING INC,2017-10-07,2017-12-15,69,5,5,,93.0,18.0,23.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,69
223,TAK-925-1001,I,NS,101,101,0.0,0.0,100.00%,1.0,0.0,MEDISCIENCE PLANNING INC,2018-09-04,2018-10-12,38,5,5,,61.0,9.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,38
224,TAK-438ODT-1001,I,GI,96,96,0.0,0.0,100.00%,1.0,0.0,Takeda PRA Development Center,2019-03-12,2019-06-17,97,5,5,,83.0,15.0,10.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,97
225,MLN0002/CCT-101,III,GI,278,292,0.0,49.0,105.04%,100.0,0.0,MEDISCIENCE PLANNING INC,2016-12-03,2017-02-20,79,5,5,,,9.0,389.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,79
226,MLN0002/CCT-001,III,GI,110,157,0.0,25.0,142.73%,60.0,0.0,MEDISCIENCE PLANNING INC,2017-11-16,2018-02-06,82,5,5,,,13.0,413.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,82
227,Azilsartan-1005,I,NonCore,23,23,0.0,0.0,100.00%,1.0,0.0,MEDISCIENCE PLANNING INC,2018-03-11,2018-04-06,26,5,5,,63.0,14.0,5.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,26
228,Niraparib-2002,II,Oncology,16,20,0.0,8.0,125.00%,30.0,0.0,MEDISCIENCE PLANNING INC,2019-07-01,2019-08-23,53,5,5,,,26.0,91.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,53
229,Niraparib-2001,II,Oncology,15,19,0.0,9.0,126.67%,30.0,0.0,MEDISCIENCE PLANNING INC,2019-03-17,2019-05-20,64,5,5,,,11.0,33.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,64
230,TAK-925-1003,I,NS,54,57,0.0,0.0,105.56%,3.0,0.0,Takeda PRA Development Center,2019-10-25,2019-11-21,27,5,5,,37.0,24.0,14.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,27
231,TAK-123-1001,I,NonCore,10,10,0.0,0.0,100.00%,1.0,0.0,PRA,2019-12-18,2020-01-10,23,5,5,,91.0,16.0,19.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,23
232,DX-2930-03,III,RGH,120,125,125.0,11.0,104.17%,60.0,0.0,IQVIA,2017-04-13,2017-05-10,27,5,5,-617.0,40.0,,219.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,27
233,DX-2930-04,III,RGH,250,0,0.0,0.0,0,60.0,0.0,"Red Maple Trials, Rho, Triumpharma",2019-10-31,2019-12-17,47,5,5,,131.0,,945.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,47
234,HGT-HIT-094,III,RGH,0,58,0.0,2.0,0,12.0,0.0,PPD,2017-09-28,2017-12-04,67,5,5,-1581.0,205.0,0.0,363.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,67
235,HGT-MLD-070,II,RGH,24,24,24.0,2.0,100.00%,6.0,0.0,ICON / MAPI / Paradigm,2017-02-20,2017-03-13,21,5,5,,214.0,166.0,319.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,21
236,PAR-C10-008,III,RGH,40,53,0.0,13.0,132.50%,12.0,0.0,Medpace,2018-01-30,2018-07-03,154,5,5,-3144.0,38.0,7.0,2192.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,154
237,ROPP-2008-01,II,RGH,120,121,121.0,28.0,100.83%,25.0,0.0,PPD,2016-04-27,2016-06-08,42,5,5,,80.0,7.0,118.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,42
238,SHP465-112,I,NS,0,24,0.0,2.0,0,10.0,0.0,PPD,2018-10-05,2018-11-16,42,5,5,,,,28.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,42
239,SHP465-308,III,NS,0,282,0.0,172.0,0,45.0,0.0,Endpoint,2019-01-18,2019-02-15,28,5,5,,,,254.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,28
240,SHP465-309,III,NS,0,89,0.0,6.0,0,45.0,0.0,PPD,2018-06-08,2018-08-21,74,5,5,,,,37.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,74
241,SHP615-301,III,NS,25,23,0.0,0.0,92.00%,25.0,0.0,IQVIA,2019-08-02,2019-09-19,48,5,5,-1232.0,151.0,32.0,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,48
242,SHP615-302,III,NS,6,3,1.0,0.0,50.00%,25.0,0.0,IQVIA,2019-08-31,2019-09-19,19,5,5,,189.0,1.0,-132.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,19
243,SHP616-300,III,NonCore,0,75,0.0,17.0,0,40.0,0.0,PPD,2017-07-24,2017-08-23,30,5,5,,262.0,22.0,231.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,30
244,SHP620-303,III,RGH,351,349,352.0,74.0,99.43%,100.0,4.0,PPD,2020-08-17,2020-11-13,88,5,5,,135.0,7.0,144.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,88
245,SHP621-101,I,GI,22,0,0.0,0.0,0.00%,1.0,0.0,0,2017-11-26,2018-01-22,57,5,5,,70.0,0.0,18.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,57
246,SHP621-102,I,GI,16,7,7.0,0.0,43.75%,1.0,0.0,0,2017-12-29,2018-03-08,69,5,5,,44.0,0.0,7.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,69
247,SHP621-301,III,GI,0,323,0.0,26.0,0,60.0,0.0,PPD,2019-02-15,2019-03-15,28,5,5,-1465.0,35.0,27.0,130.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28
248,SHP621-302,III,GI,200,219,219.0,45.0,109.50%,60.0,0.0,Endpoint,2019-11-12,2019-12-12,30,5,5,,21.0,28.0,270.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,30
249,SHP621-302,III,GI,200,219,219.0,45.0,109.50%,60.0,0.0,Endpoint,2019-11-12,2019-12-12,30,5,5,,21.0,28.0,270.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,30
250,SHP633-301,III,GI,10,10,10.0,3.0,100.00%,8.0,0.0,IQVIA,2020-09-18,2020-10-14,26,5,5,,859.0,0.0,200.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,26
251,SHP633-302,III,GI,10,10,0.0,0.0,100.00%,6.0,0.0,IQVIA,2020-01-21,2020-03-04,43,5,5,,255.0,19.0,202.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,43
252,SHP633-303,III,GI,39,29,0.0,9.0,74.36%,12.0,0.0,IQVIA,2020-07-14,2020-10-09,87,5,5,,155.0,9.0,1071.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,87
253,SHP633-304,III,GI,57,61,0.0,9.0,107.02%,28.0,0.0,TBD,2020-11-05,2021-01-25,81,5,5,,122.0,0.0,113.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,81
254,SHP633-306,III,GI,5,7,0.0,0.0,140.00%,5.0,0.0,IQVIA,2019-08-06,2019-09-13,38,5,5,,124.0,64.0,162.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,38
255,SHP634-101,I,RGH,34,34,0.0,1.0,100.00%,30.0,0.0,PPD,2019-03-08,2020-02-17,346,5,5,,36.0,24.0,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,346
256,SHP634-102,I,RGH,24,24,24.0,0.0,100.00%,1.0,0.0,Parexel,2017-06-26,2017-08-22,57,5,5,-364.0,225.0,27.0,35.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,57
257,SHP634-103,I,RGH,58,58,58.0,0.0,100.00%,1.0,0.0,"Clinical Pharmacology of Miami, INC",2017-11-03,2018-03-09,126,5,5,-121.0,22.0,14.0,4.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,126
258,SHP634-402,IV,RGH,50,36,0.0,36.0,72.00%,1.0,0.0,PPD,2019-12-20,2020-12-04,350,5,5,,39.0,44.0,903.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,350
259,SHP639-101,I,NonCore,0,63,0.0,1.0,0,7.0,0.0,PPD,2018-05-30,2018-11-13,167,5,5,-644.0,118.0,6.0,84.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,167
260,SHP640-303,III,NonCore,721,753,753.0,57.0,104.44%,203.0,0.0,IQVIA,2018-10-03,2018-11-15,43,5,5,-791.0,32.0,25.0,290.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,43
261,SHP643-101,I,RGH,32,32,0.0,0.0,100.00%,1.0,0.0,PPD,2018-05-30,2018-07-30,61,5,5,,,,112.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,61
262,SHP643-102,I,RGH,190,190,0.0,17.0,100.00%,1.0,1.0,PPD,2019-11-13,2020-01-03,51,5,5,,,,111.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,51
263,SHP647-301,III,GI,825,380,0.0,34.0,46.06%,167.0,15.0,PPD,2020-07-22,2020-12-02,133,5,5,,,92.0,91.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,133
264,SHP647-302,III,GI,825,279,0.0,21.0,33.82%,168.0,20.0,PPD,2020-07-15,2020-11-09,117,5,5,,,35.0,85.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,117
265,SHP647-305,III,GI,"1,032",30,0.0,2.0,2.91%,420.0,5.0,PPD,2020-07-07,2020-11-25,141,5,5,,,65.0,104.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,141
266,SHP647-306,III,GI,"1,032",34,0.0,7.0,3.29%,420.0,8.0,PPD,2020-08-18,2020-11-24,98,5,5,,,36.0,124.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,98
267,SHPELA-701,IV,RGH,25,5,0.0,0.0,20.00%,25.0,3.0,IQVIA,2020-05-11,2020-08-28,109,5,5,,0.0,,367.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,109
268,SPD489-348,III,NS,100,115,0.0,46.0,115.00%,54.0,1.0,Bracket,2020-01-03,2020-01-30,27,5,5,,57.0,0.0,371.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,27
269,TAK-620-1019,I,RGH,38,0,0.0,0.0,0,1.0,0.0,PPD,2019-11-25,2020-03-03,99,5,5,,29.0,28.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,99
270,TAK-620-1020,I,RGH,24,24,0.0,0.0,100.00%,1.0,1.0,TBD,2020-11-11,2021-12-15,399,5,5,,55.0,13.0,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,399
271,TAK-743-1003,I,RGH,12,12,0.0,0.0,100.00%,1.0,0.0,Celerion,2020-12-16,2021-01-26,41,5,5,,,7.0,111.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,41
272,TAK-888-2001,III,NonCore,500,0,0.0,0.0,0,30.0,0.0,0,2021-03-10,2021-03-28,18,5,5,,89.0,0.0,28.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,18
273,TED-C13-003,III,GI,42,42,0.0,0.0,100.00%,19.0,0.0,Psi,2015-01-09,2015-02-05,27,5,5,,49.0,31.0,116.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,27
274,TED-C14-006,III,GI,34,59,0.0,0.0,173.53%,27.0,0.0,IQVIA,2017-07-28,2017-10-20,84,5,5,-1019.0,129.0,21.0,210.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,84
275,DEN-001,0,NonCore,"2,000",0,0.0,0.0,0,4.0,0.0,TBD,2016-12-31,2017-01-31,31,5,5,,0.0,0.0,275.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,31
276,DEN-002,0,NonCore,"1,200",0,0.0,0.0,0,3.0,0.0,TBD,2018-07-18,2019-10-25,464,5,5,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,464
277,DEN-101,I,NonCore,72,0,0.0,0.0,0,1.0,0.0,DMID-CROMS Pharmacovigilance Group,2012-04-12,2012-12-04,236,5,5,,61.0,0.0,276.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,236
278,DEN-102,I,NonCore,112,0,0.0,0.0,0,1.0,0.0,IQVIA,2011-11-09,2013-05-01,539,5,5,,0.0,0.0,364.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,539
279,DEN-104,I,NonCore,144,0,0.0,0.0,0,3.0,0.0,TBD,2014-01-06,2014-03-01,54,5,5,,0.0,9.0,133.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,54
280,DEN-203-2,II,NonCore,360,0,0.0,0.0,0,8.0,0.0,Chiltern,2016-04-01,2016-12-30,273,5,5,,71.0,0.0,1096.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,273
281,DEN-204,II,NonCore,"1,800","1,778",1800.0,0.0,98.78%,3.0,0.0,IQVIA,2016-09-13,2020-10-02,108,5,5,,0.0,0.0,578.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1480
282,DEN-205,II,NonCore,400,351,0.0,29.0,87.75%,3.0,0.0,PPD,2017-09-18,2018-01-11,115,5,5,,130.0,5.0,385.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,115
283,DEN-304,III,NonCore,924,4,0.0,111.0,0.43%,14.0,1.0,PPD,2019-01-14,2019-05-22,128,5,5,,517.0,0.0,312.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,128
284,DEN-305,III,NonCore,900,900,0.0,160.0,100.00%,11.0,0.0,PPD,2019-05-13,2019-11-04,175,5,5,,306.0,0.0,412.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,175
285,DEN-307,III,NonCore,200,203,0.0,0.0,101.50%,0.0,0.0,IQVIA,2020-03-13,2020-12-15,277,5,5,,126.0,0.0,287.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,20.0,277
286,DEN-313,II,NonCore,200,392,0.0,16.0,196.00%,2.0,2.0,PPD,2020-09-29,2021-02-25,149,5,5,,0.0,0.0,1215.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,149
287,DEN-314,III,NonCore,900,899,0.0,121.0,99.89%,10.0,0.0,PPD,2019-07-09,2019-10-02,85,5,5,,196.0,0.0,313.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,6.0,85
288,DEN-315,III,NonCore,400,400,0.0,9.0,100.00%,5.0,1.0,PPD,2019-01-26,2019-07-25,102,5,5,,249.0,0.0,293.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,22.0,180
289,EPI-001,0,NonCore,"3,500",0,0.0,0.0,0,1.0,0.0,TBD,2017-11-13,2018-01-31,79,5,5,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,79
290,EPI-002,0,NonCore,"2,750",0,0.0,0.0,0,9.0,6.0,Assign Group,2017-03-31,2018-08-31,518,5,5,,149.0,0.0,14.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,518
291,EPI-003A,0,NonCore,"2,152",0,0.0,0.0,0,5.0,2.0,Assign Group,2017-07-07,2019-12-13,889,5,5,,0.0,0.0,76.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,889
292,EPI-008,0,NonCore,400,0,0.0,0.0,0,2.0,0.0,TBD,2016-03-23,2016-06-30,99,5,5,,0.0,0.0,8.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,99
293,EPI-011,0,NonCore,"5,000",0,0.0,0.0,0,1.0,0.0,Mediscience Planning Inc.,2017-03-31,2017-03-31,0,5,5,,78.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0
294,EPI-012,0,NonCore,"2,000",0,0.0,0.0,0,1.0,0.0,TBD,2018-03-30,2018-04-30,31,5,5,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,31
295,EPI-013,0,NonCore,0,0,0.0,0.0,0,1.0,0.0,TBD,2015-01-15,2015-01-31,16,5,5,,0.0,0.0,15.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,16
296,EPI-015,0,NonCore,100,0,0.0,0.0,0,1.0,0.0,TBD,2017-05-09,2017-06-01,23,5,5,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,23
297,EPI-017,0,NonCore,"1,242",0,0.0,0.0,0,2.0,0.0,TBD,2016-12-30,2018-04-30,486,5,5,,230.0,0.0,60.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,486
298,EPI-018,0,NonCore,495,0,0.0,0.0,0,1.0,0.0,TBD,2015-07-31,2016-06-30,335,5,5,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,335
299,EPI-020,0,NonCore,30,0,0.0,0.0,0,1.0,0.0,TBD,2018-08-15,2018-08-30,15,5,5,,0.0,0.0,758.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,15
300,EPI-026,0,NonCore,800,0,0.0,0.0,0,2.0,1.0,IQVIA,2020-04-08,2021-01-29,296,5,5,,0.0,0.0,160.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,296
301,IPV-102,I,NonCore,340,0,0.0,0.0,0,3.0,4.0,PRA Health Sciences,2018-06-29,2018-12-14,168,5,5,,135.0,0.0,183.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,168
302,LV01-101,I,NonCore,28,0,0.0,0.0,0,1.0,0.0,"DP Clinical, Inc.",2008-10-07,2009-10-12,370,5,5,,0.0,14.0,145.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,370
303,LV03-105,I,NonCore,132,0,0.0,0.0,0,5.0,0.0,"DP Clinical, Inc.",2012-02-24,2012-03-02,7,5,5,,0.0,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,7
304,NOR-107,II,NonCore,420,0,0.0,0.0,0,2.0,0.0,IQVIA,2015-06-19,2015-08-17,59,5,5,,0.0,0.0,393.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,59
305,NOR-201,II,NonCore,450,0,0.0,0.0,0,10.0,0.0,IQVIA,2016-01-14,2016-02-01,18,5,5,,46.0,0.0,561.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,18
306,NOR-202,II,NonCore,840,840,840.0,0.0,100.00%,12.0,0.0,IQVIA,2018-06-20,2018-08-30,71,5,5,,97.0,0.0,330.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,71
307,NOR-204,II,NonCore,325,320,0.0,11.0,98.46%,10.0,0.0,PPD,2017-09-29,2018-02-05,129,5,5,,33.0,0.0,392.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,129
308,NOR-210,II,NonCore,50,50,0.0,2.0,100.00%,1.0,0.0,PPD,2015-09-11,2015-10-29,48,5,5,,33.0,0.0,196.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,48
309,NOR-211,II,NonCore,"4,176","4,758",0.0,0.0,113.94%,1.0,0.0,IQVIA,2018-06-16,2018-08-08,53,5,5,,33.0,0.0,51.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,53
310,ZIK-101,I,NonCore,240,271,271.0,20.0,112.92%,9.0,8.0,PRA Health Sciences,2018-12-28,2019-05-28,151,5,5,,41.0,14.0,63.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,151
